Aurinia Pharmaceuticals (AUPH) Peer Comparison

$16.48

$-0.07 (-0.39%)

As on 27-Aug-2026 16:00EDT

Market cap

$2,215 Mln

Revenue (TTM)

$312 Mln

P/E Ratio

7.3

P/B Ratio

3.7

Div. Yield

0 %

Edit

	Aurinia Pharmaceuticals (AUPH)	Xenon Pharmaceuticals (XENE)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
Market cap ($ Mln)	2,215	5,885	3,668	352	396
Revenue ($ Mln)	312	--	66	0	59
Net Profit ($ Mln)	314.11	-409.20	-164.66	-37.54	-3.25
Net Margin (%)	100.84	--	-248.83	134,079.79	-5.49
RoE (%)	52.52	-44.86	-17.68	-79.49	-8.35
Price to Earnings	7.30	--	--	--	--
Price-To-Book	3.74	4.66	4.18	9.16	9.36

Cashflow ($ Mln)

	Aurinia Pharmaceuticals (AUPH)	Xenon Pharmaceuticals (XENE)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
Cash From Operating Activities	135.66	-279.12	-131.30	-29.06	-12.47
Cash Flow from Investing Activities	-32.77	218.00	87.75	-2.19	--
Cash from Financing Activities	-106.11	117.11	14.08	43.88	22.63
Net Cash Inflow / Outflow	--	--	--	--	--

	Aurinia Pharmaceuticals (AUPH)	Xenon Pharmaceuticals (XENE)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
ROCE (%)	51.61	-51.11	-13.12	-67.28	-40.15
ROE (%)	52.52	-44.86	-17.68	-79.49	-8.35
ROA (%)	42.65	-27.75	-11.64	-60.11	-3.23
EBIT Margin (%)	54.20	--	-304.58	133,972.64	-4.19
Net Margin (%)	100.84	-4,612.13	-248.83	134,079.79	-5.49
Cash Profit Margin (%)	0.00	--	0.00	3.35	0.00

	Aurinia Pharmaceuticals (AUPH)	Xenon Pharmaceuticals (XENE)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
Revenue Growth (%)	19.76	--	101.28	-100.20	77.83
EBIT Growth (%)	151.91	3.41	23.59	-26.93	70.81
Net Profit Growth (%)	418.03	-47.07	0.61	-26.91	72.99
EPS Growth (%)	434.98	-34.29	2.53	-6.40	73.38
Book Value Growth (%)	96.66	55.33	-13.08	12.47	531.86

	Aurinia Pharmaceuticals (AUPH)	Xenon Pharmaceuticals (XENE)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
Price / Earnings	7.70	-10.27	-6.98	-11.41	-24.64
Price / Book Value	3.81	6.11	1.06	6.66	6.85
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	14.79	-8.80	-4.24	-9.61	-27.28
Market Cap ($ Cr)	--	--	--	--	--

	Aurinia Pharmaceuticals (AUPH)	Xenon Pharmaceuticals (XENE)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
Debt to Equity	0.00	0.00	0.00	0.00	0.00
Short term debt to equity ratio	0.03	0.00	0.01	0.00	0.00
Current Ratio	5.42	21.02	12.77	6.72	5.85
Quick Ratio	4.97	21.02	12.63	6.72	5.66
Interest Coverage	17.75	--	-11.19	--	-2.43

	Aurinia Pharmaceuticals (AUPH)	Xenon Pharmaceuticals (XENE)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)	Fennec Pharmaceuticals (FENC)
Debtors to sales (%)	13.21	18.28	144.21	0.00	39.29
Asset Turnover	0.42	0.00	0.05	0.00	0.59
Receivable days	50.32	69.15	596.85	--	147.53
Inventory Days	474.76	--	40.15	--	127.22
Payable days	47.52	643.10	377.52	--	381.73
Cash Conversion Cycle	477.57	--	259.48	--	-106.97

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.